722 top medical experts on Myasthenia Gravis across 50 countries and 36 U.S. states, including 663 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of acetylcholine receptors or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). thymoma is commonly associated with this condition.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Nervous System Paraneoplastic Syndromes (656), Neuromuscular Junction Diseases (231), Autoimmune Diseases of the Nervous System (514) and Narrower Categories: Lambert-Eaton Myasthenic Syndrome (320), Neonatal Myasthenia Gravis (17).
  4. Clinical Trials ClinicalTrials.gov : at least 71 including 4 Active, 33 Completed, 15 Recruiting
  5. Synonyms: Anti-MuSK Myasthenia Gravis, MuSK MG, MuSK Myasthenia Gravis, Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis, Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis


  

        

                    


    Computing Expert Listing ...

);